Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 18, 2015
- Accepted in final form April 4, 2016
- First Published May 10, 2016.
Author Disclosures
- Elysse M. Knight, PhD,
- Soong Ho Kim, PhD,
- Jessica C. Kottwitz, BS,
- Asa Hatami, PhD,
- Ricardo Albay, BS,
- Akinobu Suzuki, PhD,
- Alex Lublin, PhD,
- Cristina M. Alberini, PhD,
- William L. Klein, PhD,
- Paul Szabo, PhD,
- Norman R. Relkin, MD, PhD,
- Michelle Ehrlich, MD,
- Charles G. Glabe, PhD,
- Sam Gandy, MD, PhD and
- John W. Steele, PhD
- Elysse M. Knight, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Baxter (salary support)
(1) NIH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Soong Ho Kim, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jessica C. Kottwitz, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Asa Hatami, PhD,
NONE
NONE
NONE
1) Journal of Alzheimer's Disease, Associate Editor, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) NIH AG 033069, graduate student, 5 2) NIH AG 00538, graduate student, 5
NONE
1) Cure Alzheimer's Fund
NONE
NONE
NONE
NONE
NONE
NONE
- Ricardo Albay, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Akinobu Suzuki, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alex Lublin, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Sanofi Genzyme, Senior Manager, 1 year
NONE
NONE
NONE
NONE
NONE
NONE
University of California, Riverside
NONE
NONE
NONE
NONE
NONE
(1) Geron, 1.5 years, (2) Ionis, 1 Year
NONE
- Cristina M. Alberini, PhD,
NONE
NONE
NONE
2004-present Member of the Editorial Board of Neural Plasticity 2004-present Member of the Editorial Board of Cell Science Journal 2007-2014 Associate Editor, Frontiers in Neuroscience2008-present Member of the Editorial Board of Neurobiology of Learning and Memory
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01 MH065635
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- William L. Klein, PhD,
(1) Acumen Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH, R01 AG029460, PI, 2008-2011(2) NIH, R01 AG022547, PI, 2007-2011(3) NIH, R21 AG045637, PI, 2014-2016(4) NIH, R21 AG041953, PI, 2012-2014
(1) Baxter-NU Alliance(2) NUCATS/Northwestern
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul Szabo, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Norman R. Relkin, MD, PhD,
(1) Anavex(2) Herbal Science Group(3) Eisai
NONE
NONE
Associate Editor of Neurology Alert. 1993-2015
Pending Patents:1. Multiplexed CSF markers for Alzheimer's disease -Describes use of multiple CSF proteomic markers for diagnosis of Alzheimer's disease2. Diffusion tensor histogram analysis for Diagnosis of HydrocephalusAn analytic method for identifying a DTI pattern associated with Normal Pressure Hydrocephalus3. Volumetric MRI for predicting response to IVIG treatment of Alzheimer's diseaseDescribes methods for measuring change in brain volume in response to IVIG for Alzheimers4. Cytokine analysis for predicting response to IVIG treatment of Alzheimer's diseaseDescribes methods for using plasma and CSF cytokine profile as measures of response to IVIG for Alzheimers5. Systems and Methods for automating the retrieval of partitioned search resultsTechniques for rapidly obtaining large online datasets
1. Neuroimaging Studies in the Evaluation of Dementia, May 2015, UpToDate
NONE
(1) Eisai(2) Forest(3) Hydrocephalus Association
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Forest, Expert Witness 2015-2016
- Michelle Ehrlich, MD,
NONE
NONE
NONE
ASN Neuro, Editorial board, since formation of journal
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)NIH, 1R01NS081282-01A1, PI(2NIH,1R01AG04617001,PI(MPI)
NONE
(1)NYSTEM,N13G169 , PI
NONE
NONE
NONE
NONE
NONE
NONE
- Charles G. Glabe, PhD,
NONE
NONE
NONE
Journal of Molecular Neurodegeneration
several issued and pending patents regarding immunotherapy and immunodiagnostics for AD
NONE
NONE
several issued and pending patents regarding immunotherapy and immunodiagnostics for AD
NONE
NONE
NONE
NONE
NIH AG00538
NONE
Cure Alzheimer's fund
NONE
Antibodies for research purposes only, various companies
Royalties from antibody licensing for research purposes only. 2003-2016 various antibodies
NONE
NONE
Same as #8 above.Sidley, LLP; analysis of IP issues, 2015
- Sam Gandy, MD, PhD and
Neurotrope (bryostatin treatment for AD)
NONE
NONE
Associate Editor, ADAD; Associate Editor, Molecular Neurodegeneration; Consulting Editor, JCI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Avid/Lilly (donate PET ligand)Constellation Wines (grapeseed extract RCT in AD)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John W. Steele, PhD
Board of Directors, Scientific Advisory Board Member: OrPhi Therapeutics Inc
NONE
NONE
Associate Editor-In-Chief, Journal of Postdoctoral Research (2012-2014)Contributing Editor, Journal of Postdoctoral Research (2014-2016)
Pending: Mitoprotection for treatment of lysosomal storage diseases
NONE
NONE
Consultant: Amicus Therapeutics (Jan-Feb, 2014), Commercial Entity
NONE
NONE
NONE
NONE
NIH/NIGMS K12GM068524 (PostDoc) Feb 2014 - PresentNIH/NIGMS 5T32GM062754 (Pre-Doctoral Trainee) June 2008 - July 2011
NONE
CurePSP Foundation, Investigator Initiated Award (PI) July 2014 - PresentDPD Deficiency Foundation, Investigator Initiated Award (PostDoc) June 2013 - Jan 2014
Co-Founder, Board of Directors: OrPhi Therapeutics Inc
NONE
NONE
Amicus Therapeutics, Inc (2013-14)
GalaxoSmithKline (2015-16)
NONE
- From the Departments of Psychiatry (E.M.K., S.H.K., J.C.K., A.L., S.G., J.W.S.), Neurology (E.M.K., S.H.K., J.C.K., A.L., M.E., S.G., J.W.S.), and Pediatrics (M.E.), and Alzheimer's Disease Research Center (E.M.K., S.H.K., J.C.K., A.L., M.E., S.G., J.W.S.), Icahn School of Medicine at Mount Sinai, New York, NY; Department of Molecular Biology and Biochemistry (A.H., R.A., C.G.G.), University of California at Irvine; King Fahd Medical Research Center (A.H., R.A., C.G.G.), KAU, Jeddah, Saudi Arabia; Department of Biochemistry (A.S.), Faculty of Medicine, Graduate School of Medicine & Pharmaceutical Sciences, University of Toyama, Japan; Center for Neural Science (C.M.A.), New York University, NY; Northwestern University (W.L.K.), Chicago, IL; Department of Neurology and Brain Mind Research Institute (P.S., N.R.R.), Weill Cornell Medical College, New York, NY; Biochemistry Department (C.G.G.), Faculty of Science and Experimental Biochemistry Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; James J. Peters VA Medical Center (S.G.), Bronx, NY; and Sanford Consortium for Regenerative Medicine (J.W.S.), University of California San Diego, La Jolla, CA.
- Correspondence to Dr. Gandy: Samuel.Gandy{at}mssm.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
A phase 3 trial of IV immunoglobulin for Alzheimer diseaseNorman R. Relkin, Ronald G. Thomas, Robert A. Rissman et al.Neurology, April 05, 2017 -
Article
Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse modelJohn R. Cirrito, Clare E. Wallace, Ping Yan et al.Neurology, September 10, 2020 -
Article
HACE1 deficiency leads to structural and functional neurodevelopmental defectsVanja Nagy, Ronja Hollstein, Tsung-Pin Pai et al.Neurology: Genetics, April 30, 2019 -
Views & Reviews
Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?Bruno P. Imbimbo, Ugo Lucca, Mark Watling et al.Neurology: Genetics, December 17, 2020